4basebio H1 2022 Half-Year Results Report

4basebio PLC reported H1 2022 results highlighting first DNA sales, commissioned clean rooms for manufacturing, and three patent filings in synthetic DNA and non-viral vector technology. The company generated £5.6 million in cash with expected runway into 2023 and plans to implement GMP manufacturing processes during 2023.